Monitor upcoming durability data in 2H 2026 and Phase 2b results in 2027, which will be critical for confirming the drug's long-term efficacy and dosing advantage. The strong safety profile reduces regulatory risk for future trials.
Price Chart
Executive Summary
Oruka Therapeutics announced positive Phase 2a trial results for its anti-IL-23 antibody ORKA-001 in psoriasis, showing 63.5% of patients achieved complete skin clearance (PASI 100) at 16 weeks with a favorable safety profile. The data supports potential annual dosing and positions ORKA-001 as a best-in-class therapy in a $30B+ market.
Key Facts
- 63.5% of ORKA-001-treated patients achieved PASI 100 (complete skin clearance) at Week 16 vs. 4.8% for placebo (p < 0.0001)
- Favorable safety profile: no serious adverse events in treatment arm, TEAE rate (50.8%) lower than placebo (57.1%)
- Updated PK data supports potential for annual dosing, with drug concentrations remaining above effective levels for a full year
- Phase 2b trial (EVERLAST-B) ongoing with data expected in 2027 to support Phase 3 initiation
- Company is well-funded with cash runway into Phase 3 for ORKA-001
Financial Impact
Significant positive impact on valuation potential in a $30B+ psoriasis market
Risk Factors
- Phase 2a results may not be replicated in larger Phase 3 trials
- Competitors in the IL-23 inhibitor space could respond with improved data or pricing
- Longer-term safety data could reveal issues not seen in the 16-week trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-047743 |
| Document: ea028778201ex99-2.htm | 0001213900-26-047743 |
| Document: ea028778201ex99-1.htm | 0001213900-26-047743 |
| Document: 0001213900-26-047743-index-headers.html | 0001213900-26-047743 |
| Document: 0001213900-26-047743-index.html | 0001213900-26-047743 |
| Document: 0001213900-26-047743.txt | 0001213900-26-047743 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access